Drug intelligence / Profile preview

NAL3220

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

NAL3220 is a transdermal antiviral patch being developed by NAL Pharmaceutical Group for the treatment of shingles (herpes zoster). The product utilizes a proprietary transdermal delivery system to provide a controlled, sustained release of an antiviral agent directly through the skin. This delivery method is intended to offer therapeutic advantages over traditional oral or topical treatments, such as improved bioavailability, reduced systemic side effects, and enhanced patient compliance. NAL3220 is currently in the preclinical stage of development.

Other names: Antiviral Patch

Beyond the preview

Go deeper on NAL3220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL3220.

Explore the full profile